Genelux Q3 EPS Increased by Brookline Capital Management

Genelux Co. (NASDAQ:GNLX) – Brookline Capital Management increased their Q3 2025 earnings per share estimates for shares of Genelux in a research report issued on Tuesday, May 6th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their previous estimate of ($0.21). The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s FY2025 earnings at ($0.83) EPS.

GNLX has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Genelux in a research note on Monday, March 31st. Benchmark decreased their target price on Genelux from $25.00 to $23.00 and set a “speculative buy” rating for the company in a research report on Thursday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Genelux presently has an average rating of “Buy” and an average target price of $17.75.

Genelux Stock Up 3.9 %

NASDAQ:GNLX opened at $2.96 on Friday. Genelux has a twelve month low of $1.60 and a twelve month high of $5.89. The company has a fifty day moving average of $2.96 and a 200-day moving average of $3.11. The firm has a market capitalization of $111.70 million, a P/E ratio of -3.12 and a beta of -0.33.

Genelux (NASDAQ:GNLX) last issued its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03.

Institutional Investors Weigh In On Genelux

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. bought a new stake in Genelux during the 1st quarter worth approximately $68,000. Liberty Wealth Management LLC bought a new stake in Genelux during the first quarter worth $45,000. Woodward Diversified Capital LLC raised its position in Genelux by 15.2% in the 1st quarter. Woodward Diversified Capital LLC now owns 1,461,113 shares of the company’s stock valued at $3,945,000 after buying an additional 192,808 shares during the last quarter. 5T Wealth LLC bought a new position in Genelux during the 1st quarter valued at $49,000. Finally, Advisor Resource Council purchased a new position in Genelux during the 1st quarter worth $34,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.